Date: 2014-10-15
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Santen Pharmaceutical (Japan)
Therapeutic area: Ophtalmological diseases
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
Disease:
Details: * On October 15, 2014, Santen Pharmaceutical announced its new wholly owned subsidiary in Italy. Following the acquisition of Merck & CoGlaucoma franchise, Santen commercial team is launched in Italy to promote products SAFLUTAN® and COSOPT®. As a specialty company dedicated to ophthalmology for over 120 years, Santen delivers products to customers in more than 50 countries. Thanks to Merck\'s transaction in ophthalmology, Santen has strengthened its lineup of glaucoma products and expands its footprint in Europe. The launch of its own sales force in Italy crystallizes Santen\'s long term corporate vision to become \"a specialized pharmaceutical company with a global presence\". It comes on the heels of Santen\'s latest initiatives that the company has increased its presence in Germany, North Europe, then in Central and East Europe, and more recently in France. Italian launch paves the way for future launch of Santen\'s new products in the country.
Financial terms:
Latest news:
